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Understanding immune alterations in cancer patients is a major challenge and requires
precise phenotypic study of immune subsets. Improvement of knowledge regarding the
biology of natural killer (NK) cells and technical advances leads to the generation of high
dimensional dataset. High dimensional flow cytometry requires tools adapted to complex
dataset analyses. This study presents an example of NK cell maturation analysis in Healthy
Volunteers (HV) and patients with Acute Myeloid Leukemia (AML) with an automated
procedure using the FLOCK algorithm. This procedure enabled to automatically identify
NK cell subsets according to maturation profiles, with 2D mapping of a four-dimensional
dataset. Differences were highlighted in AML patients compared to HV, with an overall
increase of NK maturation. Among patients, a strong heterogeneity in NK cell maturation
defined three distinct profiles. Overall, automatic gating with FLOCK algorithm is a recent
procedure, which enables fast and reliable identification of cell populations from high-
dimensional cytometry data. Such tools are necessary for immune subset characterization
and standardization of data analyses. This tool is adapted to new immune cell subsets
discovery, and may lead to a better knowledge of NK cell defects in cancer patients.
Overall, 2D mapping of NK maturation profiles enabled fast and reliable identification of
NK cell subsets.
Keywords: AML, NK maturation, automated gating, FLOCK algorithm, multidimensional flow cytometry
INTRODUCTION
Natural Killer (NK) cells are immune effectors that play a key role in tumor rejection, with an ability
to detect and lyse tumor cells without prior stimulation (1–3). Their fundamental role in anti-tumor
immune response has been widely demonstrated in both solid tumors and malignant hemopathies,
and parameters linked to NK cell activation can either be prognostic factors (4–9) or predictive
markers of response to chemotherapy or radiotherapy (10, 11). Thus,monitoringNK cell parameters
seems to be an important point to stratify patients at diagnosis and to assess NK cell response
during the course of treatment. For such applications, NK cell alterations in cancer patients need
to be further described in order to dissect mechanisms involved and define the relevant therapeutic
strategies based on NK restoration (12, 13).
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In addition to classical NK activating receptors, maturation is
fundamental for triggering immune response while maintaining
self tolerance (14). NK cell maturation and activation are intrin-
sically linked (14). Therefore, this point is probably of primary
importance for NK cell reactivity in the context of malignancies.
Recent studies highlight increasing number ofmarkers that define
NK cell subsets according to maturation parameters. In mice,
some parameters appear as relevant markers to define NK cell
clusters according tomaturation process, such as CD16 or CD11b,
CD27, and Mac-1, which define NK subsets with progressive
acquisition of NK cell effector functions (14–17). In Humans,
four parameters further define NK cell subsets according to the
expression of NKG2A, KIR, CD57, and CD56 (16, 18). NK cells
initially differentiate from immature CD56bright to CD56dull phe-
notype, with different functions, including cytotoxicity, cytokine
production, and migratory capacities (14, 19, 20). Subsequently,
NK cells lose expression of NKG2A, and sequentially express
CD57 and KIR. Accordingly, five states of maturation stages are
defined according to expression of these markers.
To date, an increasing number of NK cell activation and matu-
ration markers have been described (17, 21). The improvement of
knowledge regarding the biology of NK cells led to an increase of
markers required to phenotypically and functionally characterize
these cells (21). Technological advances in the field of flow and
mass cytometry led to the development of complex panels to study
NK cells, with subsequent generation of high dimensional dataset
(21). In this context, manual processing of the data presents
many limitations. First, generation of gates in two dimensions is
time-consuming, and subject to operator subjectivity (22). Hence,
gating strategy can impact on results and conclusions when mul-
tiple gates are drawn [(22); Gondois-Rey et al. manuscript in
preparation]. Second, the high number of results generated is
sometimes hard to interpret and summarize, in particular when
large cohorts of patients are analyzed. Another problem is the
global comprehension of a complex system and interpretation of
results when conclusions are drawn parameter by parameter. New
tools are then required to address these problems. Recently, algo-
rithms for automatic gating and 2Dmapping of high dimensional
dataset have been developed, such as Spade (23), viSNE (24),
flowClust (22), or FLOCK (25, 26). These algorithms combined
to classification methods enable the visualization of multiple
parameters and summarize information. These approaches are of
particular importance to enable data visualization, in particular
in the context of study of complex systems such as immunity.
The present study is an example of application of NK matu-
ration profiling in Healthy Volunteers (HV) and patients with
AcuteMyeloid Leukemia (AML) using automated analysis of flow
cytometry data.
PATIENTS AND METHODS
Patients and Healthy Volunteers
Fresh peripheral blood samples were prospectively collected from
AML patients (N = 18) at diagnosis before induction chemother-
apy and from aged-matched healthy volunteers (N= 18). All
participants gave written informed consent in accordance with
the Declaration of Helsinki. Patients above 65 years at diagnosis
were excluded. The entire research procedure was approved by the
ethical review board (Institut Paoli-Calmettes Marseille, France).
Table 1 lists the baseline characteristics of patients.
Flow Cytometry
A FACS Canto II (BD Biosciences, San Jose, CA, USA) was
used for flow cytometry. NK cells from whole blood EDTA were
immunostained with Krome Orange-conjugated anti-CD45, Phy-
coerythrin cyanin 7 (PC7)-conjugated anti-CD3, allophycocyanin
(APC)-conjugated anti-CD56, fluorescein isothiocyanate (FITC)-
conjugated anti-CD158b1b2j, FITC-conjugated anti-CD158a,h
(further referred to as KIR), APC-alexafluor 750 (APC AF 750)-
conjugated anti-CD159 (NKG2A), pacific blue-conjugated anti-
CD57. All the antibodies used in the study were a kind gift of
Beckman Coulter, Marseille, France. Red blood cells were lysed
with BD FACS Lysing solution (BD Biosciences) before data
acquisition.
Cluster Identification Procedure
FCS files were read, compensated, transformed, and exported
using flowCore (R, Bioconductor) (27). FLOCK algorithm was
then applied to each exported data file (26). Resulting gated data
were imported with R. Centers of populations were extracted,
assembled, and exported as a unique tabulated text file using R.
MeV permitted heatmap visualization and hierarchical clustering
(28). Centers were clustered using euclidean distance. The tree of
centers was cut at a threshold that results in clusters with homo-
geneous mean fluorescence intensity (MFI) profile. Those clear
populations were annotated using expert knowledge. The auto-
mated gating and cluster identification procedure was described
by Gondois-Rey et al. (manuscript in preparation).
Statistical Analyses
Statistical analyses were performed using GraphPad Prism
(GraphPad Software, San Diego, CA, USA). Differences in the
distribution of continuous variables between categories were
analyzed by either Mann–Whitney test (for comparison of two
groups) or Kruskal–Wallis with Dunns’ post test (comparison of
three or more groups). Statistical significance was set at P< 0.05.
RESULTS
Automatic Gating with FLOCK
Provides Reliable Results
Multiparametric flow analysis of NK cell subsets has become
complex over recent years with the identification of several subsets
of NK cells depending on classical activating receptors, inhibitory
receptors, and maturation markers. More importantly, it has
become evident that rare subsets may be under or overestimated
during manual analysis by different investigators and different
software. We have, therefore, searched for a more reliable tool
to provide unbiased analysis of NK cell subsets in the periph-
eral blood of AML patients. First, PBMCs from healthy donors
(N = 18) and AML patients at diagnosis (N = 18) were isolated
and stained for CD56, CD3, KIR (see PATIENTS AND METH-
ODS), NKG2A, and CD57. Then CD3 CD56+ live NK cells were
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TABLE 1 | Patients characteristics.
Characteristic All AML group 1 AML group 2 AML group 3
Patients (no.) N 18 7 5 6
Age at diagnosis Mean (SD) 52:2 (13:2) 52:6 (14:8) 56:2 (7:1) 48:4 (16:0)
Sex ratio, M/F 1:57 0:43 4:00 2:00
FAB category N (%)
M0 2 (11:1) 1 (14:3) 1 (20:0) 0 (0:0)
M1 5 (27:8) 1 (14:3) 2 (40:0) 2 (33:3)
M2 5 (27:8) 2 (28:6) 1 (20:0) 2 (33:3)
M3 0 (0:0) 0 (0:0) 0 (0:0) 0 (0:0)
M4 1 (5:6) 1 (14:3) 0 (0:0) 0 (0:0)
M5 3 (16:7) 2 (28:6) 0 (0:0) 1 (16:7)
M6 1 (5:6) 0 (0:0) 1 (20:0) 0 (0:0)
M7 0 (0:0) 0 (0:0) 0 (0:0) 0 (0:0)
Unclassified 1 (5:6) 0 (0:0) 0 (0:0) 1 (16:7)
Status at diagnosis N (%)
De novo 13 (72:2) 6 (85:7) 4 (80:0) 3 (50:0)
t-AML 4 (22:2) 0 (0:0) 1 (20:0) 3 (50:0)
s-AML 1 (5:6) 1 (14:3) 0 (0:0) 0 (0:0)
White blood cell (109 cells/L) Median (SD) 9:5 (51:4) 24:7 (41:2) 10:2 (14:0) 7:4 (77:6)
Cytogenetic prognosis N (%)
1 1 (5:6) 1 (14:3) 0 (0:0) 0 (0:0)
2 12 (66:7) 3 (42:9) 4 (80:0) 5 (83:3)
3 5 (27:8) 3 (42:9) 1 (20:0) 1 (16:7)
ELN
Favorable 3 (16:7) 1 (14:3) 2 (40:0) 0 (0:0)
Intermediate 10 (55:6) 3 (42:9) 2 (40:0) 5 (83:3)
Unfavorable 5 (27:8) 3 (42:9) 1 (20:0) 1 (16:7)
Blasts (blood) at diagnosis Mean (SD) 42:6 (34:4) 37:6 (27:7) 53:0 (44:2) 39:8 (37:2)
Blasts (BM) at diagnosis Mean (SD) 63:7 (29:2) 56:9 (24:9) 73:0 (34:8) 63:8 (32:0)
initially manually pre-gated, exported, and then analyzed with
FLOCK algorithm.
Results obtained with manual gating were compared with
results obtained with FLOCK. Annotated clusters were merged
and graphically compared to the equivalent subsets obtained with
manual gating (Figure 1A). Frequencies of FLOCK-gated and
manually gated subsets of NK cells in HV samples with respect
to CD56, CD57, KIR expression were comparable (Figure 1B).
Thus, for each sample, proportions of NK cells within the dif-
ferent clusters with the two approaches were found to be fully
consistent.
Automated Gating with FLOCK Algorithm
Evidences NK Subpopulations
Natural killer cell maturation profiles in HV and AML patients
were defined according to FLOCK output. For cluster annotation
of FLOCKoutput data, we used an unsupervised hierarchical clus-
tering with MeV (Figures 2A,B). Overall, the procedure enabled
identification of five subsets of NK cells based on the expression
of CD56, CD57, KIR, and NKG2A in both patients and healthy
volunteers. NK cell differentiate from CD56bright to CD56dim phe-
notype. CD56bright phenotype then defines the most immature
subset of circulating NK cells. In CD56dim NK cells, expression
of NKG2A, KIR, and CD57 define several maturation stages (18).
Automatic gating procedure with FLOCK enable identification of
these different subsets of NK cells, with CD56bright NK cells, and
among CD56dim cells, four subsets defined by the positivity or the
negativity of KIR and CD57 (Figures 2A,B). In accordance with
previous studies, KIR positivity inversely correlates with NKG2A
expression, in both HV and AML patients (18, 29). We then
considered the repartition of NK cells within the different clusters.
On average, the percentage of CD56bright cells was found to be
significantly lower in AML patients compared to HV (1.3 3.2%
vs. 6.4 5.8%, respectively; P= 0.001) (Figures 2C,D).
Overall, 2D mapping of NK maturation profiles enabled the
visualization of high dimensional dataset as well as fast and reli-
able identification of NK cell subsets. With this unsupervised
automated gating of NK cells with four parameters, the algorithm
was able to distinguish all the NK subsets that were previously
described in the literature, but did not identify any new popu-
lation. Notably, NKG2A was not informative in NK cell cluster
definition by the algorithm.
AML Patients Present Distinct
Maturation Profiles
Patients and HV were clustered according to the percent-
ages of NK cells represented in the CD56bright, KIR /CD57 ,
KIR+/CD57 , KIR /CD57+, KIR+/CD57+ clusters with MeV
using unsupervised hierarchical clustering (HClust, Pearson cor-
relation) (Figure 3). This representation allowed defining three
distinct groups of patients. The first group of patients (N = 7)
presented a NK cell maturation profile with 50% (range: 40–67%)
NK cells in the cluster KIR /CD57  cluster. Considering the
repartition of NK cells within the different clusters, there was no
significant difference between this group and HV. The second
group of patients (N = 5) presented an intermediate maturation
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FIGURE 1 | Comparison of manually gated data and FLOCK analysis. (A) NK clusters were automatically defined by FLOCK and manually annotated as
CD56bright or CD56dim NK cells, among which four additional subsets were defined according to KIR and CD57 expression. For a given sample, clusters were defined
by FLOCK. The clusters were merged when corresponding to the same NK subpopulation and visualized with FlowJo for comparison with manual gating. Each color
represents the merging of clusters corresponding to the same population. (B) Frequencies of FLOCK and manually gated subsets of NK cells with respect to CD56,
CD57, KIR expression. Data are presented as meanSD of Healthy Volunteers (N= 18).
profile, with 43% (range: 30–52%) NK cells in the KIR /CD57 
cluster and 37% (range: 28–48%) NK cells in the KIR+/CD57+
cluster. For this group, the proportion of NK cells in the CD56bright
cluster was significantly lower than HV (P= 0.05). Of note, the
apparent high frequency of cells in the cluster KIR+/CD57+
was not significantly different from HV. The third group of
patients (N= 6) presented an hyper-maturation profile, with
proportions of NK cells of 13% (range: 7–24%) NK cells in
the KIR /CD57  cluster and 58% (range: 34–83%) NK cells
in the KIR+/CD57+ cluster. For this group, the proportion of
NK cells in the KIR /CD57  cluster was significantly lower
than HV (P< 0.05) whereas the proportion of NK cells in the
KIR+/CD57+ cluster was significantly higher (P< 0.01).
In conclusion, we observed that NK cells in AML patients
display marked differences compared to HV, with a strong inter-
individual variability, defining three distinct groups of patients
according to NK maturation profiles.
DISCUSSION
Accumulating evidence highlights NK cell parameters as potential
prognostic factors in cancer patients, which provides a strong
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FIGURE 2 | NK maturation in HV and AML patients. NK maturation profiles in HV (A) and AML patients (B) were defined according to FLOCK output and NK
subpopulations were represented using Manhattan Hierarchical Clustering based on CD56, KIR, NKG2A, and CD57 expression. Five clusters were defined; each
individual is represented in three to five clusters, depending on the presence or absence of NK cells in the different clusters. Percentages of NK cells within clusters
are presented as meanSD in HV (C) and AML (D).
rationale for developing therapeutic strategies aiming at restoring
NK cell functions (4–9). However, reaching this point warrants
better characterization of NK cell alterations in cancer patients as
well as elucidation of the mechanisms involved (30, 31).
Among important parameters involved in NK cell func-
tions, the maturation process is of particular importance; since,
depending on the maturation stage NK cells will gain or lose
important functions, such as migration capacities, effector func-
tions, response to cytokines, proliferative capacities, IFN-γ pro-
duction, or cytotoxic activity (8, 14, 32). All these functions
are absolutely required for a functional effect against tumor
cells. Thus alteration of the maturation process is likely to
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FIGURE 3 | AML patients can be classified into three distinct groups according to NK maturation profiles. Left panel: patients and HV were grouped
according to the percentage of NK cells represented in the CD56bright, KIR /CD57 , KIR+/CD57 , KIR /CD57+, KIR+/CD57+ clusters using hierarchical
clustering (HClust, Pearson correlation). This second step of clusterization enabled to define three distinct groups of patients. The frequency of NK cells in each subset
for each individual is presented in the right panel. The dashed lines represent the mean frequencies of NK subpopulations in HV and in the three groups of patients.
impact NK cell functions, with direct consequences on patients’
survival (33).
Natural killer cell maturation is a multistep process marked
by differential expression of many markers, among which CD56,
NKG2A,KIR, andCD57 are of particular importance (18).NKcell
subsets can also be defined according to the expression of CD16
and CD56. For instance, it has been described discrete stages of
NK cell differentiation. First, CD56bright NK cells expressing low
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levels of CD16 correspond to a transition between early immature
CD56bright CD16  NK cells and CD56dim CD16+ NK cells (34).
Variations of NK cells in these different compartments have been
described in several clinical conditions such as HIV infection
and in aging (13). In addition, another NK cell population of
CD56 CD16+ cells has been described and found expanded in
particular pathological conditions such as HIV or hepatitis C
virus infection (35, 36). Although these discrete stages have been
evidenced, the functions of these cells remain elusive, particularly
in the context of AML.
Whether NK maturation is impacted by the close proximity
with leukemic blasts is an important question. Under physiolog-
ical conditions, circulating NK cells differentiate from CD56bright
to CD56dim phenotype. Then NK cells lose NKG2A expression,
and gain KIR expression. CD57 is acquired at later stages of dif-
ferentiation, and defines a subset of NK cells with low proliferative
capacities and high cytotoxic potential (16, 18). In our study, we
show that NK cells in AML patients present marked differences
compared to Healthy Volunteers. The proportion of CD57+ NK
cells is increased in one-third of patients, at the expense of less
mature NK subsets, with a drastic decrease of immature NK
cells. Although CD57+ NK cells have been described as the most
cytotoxic subset of NK cells, in the context of AML, we still need
to check whether these cells display efficient cytotoxic activity on
cancer target cells. In addition, the impact of these extreme mat-
uration profiles on clinical outcome warrants further exploration
on a larger cohort of patients.
Natural killer cell maturation has been studied in human
breast and lung cancer (37, 38). In contrast to our study, tumor-
infiltrating NK cells display an immature phenotype, with high
percentages of CD56bright NK cells compared to healthy tissues.
A notable difference in our study is that we analyzed periph-
eral blood cells, whereas the previously cited studies were done
with infiltrating NK cells. Mamessier et al. hypothesized that
NK cells were de-differentiated rather than immature cells; this
could explain the high proportion of CD56bright in tumor tissue,
without direct impact on central NK maturation or migration
of the most immature cells on the tumor site. One additional
difference in the context of AML is that NK cells maturate in close
contactwith tumor cells. This could explain the high proportion of
highly maturated NK cells. However, some authors also described
CD56dimCD57+ enrichment in tumor-infiltrated lymph nodes in
patients with metastatic melanoma, with significant impact on
patients’ survival (33).
Technical advances in flow and mass cytometry now enable
the dissection of NK cell biology with high precision, with the
subsequent need for tools adapted to the analysis of datasets with
unprecedented dimensionality (21, 25, 39). In our study, we used
an automated procedure using the FLOCK algorithm and hier-
archical clustering, which enabled unsupervised identification of
NK subsets and patients profiling based on NK parameters. Auto-
matic gating algorithms are powerful and reliable tools adapted to
high dimensional dataset analysis (25, 40) with potential limita-
tions highlighted in the case of rare populations (40, 41). In the
case of immunomonitoring studies on large cohorts of patients,
the development of such approaches is of primary importance for
data analysis standardization. First, the high number of subjects
included in these studies requires automated gating in order to
reduce the time of analysis. Second, visualization of all the clusters
allows fast and unsupervised identification of cell populations.
Moreover, the hierarchical classification of patients according to
maturation profiles enables the discovery of distinct patterns or
specific subgroups among patients. The clinical consequences
of such observations should be evaluated on larger cohorts of
patients. Considering the potential impact of NK maturation on
clinical outcome, NK cell maturation profiling might be informa-
tive in prognostic immune signatures and may find applications
in patients’ stratification at diagnosis.
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